CLINICAL TRIALS PROFILE FOR DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for donepezil hydrochloride; memantine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Development Center for Biotechnology, Taiwan | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Program Office, National Science & Technology, Biotechnology & Pharmaceuticals | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Taipei Veterans General Hospital, Taiwan | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | National Taiwan University Hospital | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00181298 ↗ | Memantine in Systemic Lupus Erythematosus | Completed | Forest Laboratories | N/A | 2006-03-01 | Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor. |
| NCT00181298 ↗ | Memantine in Systemic Lupus Erythematosus | Completed | Johns Hopkins University | N/A | 2006-03-01 | Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor. |
| NCT00234637 ↗ | Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment | Completed | Novartis | Phase 4 | 2003-11-01 | This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase. After completion of assessments at the end of the run-in phase, patients who were not sufficiently stabilized on rivastigmine alone will receive add-on memantine to their rivastigmine treatment; patients who were stabilized on rivastigmine alone will have completed and be discontinued from the study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for donepezil hydrochloride; memantine hydrochloride
Condition Name
Condition MeSH
Clinical Trial Locations for donepezil hydrochloride; memantine hydrochloride
Trials by Country
Clinical Trial Progress for donepezil hydrochloride; memantine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for donepezil hydrochloride; memantine hydrochloride
Sponsor Name
| Sponsor Name for donepezil hydrochloride; memantine hydrochloride | |
| Sponsor | Trials |
| Forest Laboratories | 4 |
| Johns Hopkins University | 2 |
| Program Office, National Science & Technology, Biotechnology & Pharmaceuticals | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
